Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

ClinicalTrials.gov ID: NCT00283751

Public ClinicalTrials.gov record NCT00283751. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.

Study identification

NCT ID
NCT00283751
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
583 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2003 (Type not available)
Primary completion
Nov 2004 (Actual)
Completion
Nov 2004 (Actual)
Last update posted
Jan 27, 2017

2003 – 2004

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Novo Nordisk Investigational Site Greenbrae California 94904 —
Novo Nordisk Investigational Site La Mesa California 91942 —
Novo Nordisk Investigational Site West Palm Beach Florida 33401 —
Novo Nordisk Investigational Site Atlanta Georgia 30318 —
Novo Nordisk Investigational Site Chicago Illinois 60607 —
Novo Nordisk Investigational Site Springfield Illinois 62711 —
Novo Nordisk Investigational Site Topeka Kansas 66606 —
Novo Nordisk Investigational Site Chesterfield Missouri 63017 —
Novo Nordisk Investigational Site St Louis Missouri 63141 —
Novo Nordisk Investigational Site Lincoln Nebraska 68521 —
Novo Nordisk Investigational Site Pleasantville New Jersey 08232 —
Novo Nordisk Investigational Site Cleveland Ohio 44195 —
Novo Nordisk Investigational Site Kettering Ohio 45429 —
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19140 —
Novo Nordisk Investigational Site Mt. Pleasant South Carolina 29464 —
Novo Nordisk Investigational Site Dallas Texas 75230 —
Novo Nordisk Investigational Site Dallas Texas 75246 —
Novo Nordisk Investigational Site Dallas Texas 75390-8858 —
Novo Nordisk Investigational Site San Antonio Texas 78229 —
Novo Nordisk Investigational Site Warrenton Virginia 20186 —
Novo Nordisk Investigational Site Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00283751, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 27, 2017 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00283751 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →